About Congenica
Congenica is a company based in Cambridge (United Kingdom) founded in 2013 by Nick Lench, Richard Durbin, and Matthew Hurles was acquired by SeqOne in September 2025. Congenica has raised $81.91 million across 11 funding rounds from investors including Tencent, BGI and Downing. The company has 79 employees as of December 31, 2020. Congenica offers products and services including Congenica Platform and Clinical Interpretation Services. Congenica operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Unity Biotechnology, among others.
- Headquarter Cambridge, United Kingdom
- Employees 79 as on 31 Dec, 2020
- Founders Nick Lench, Richard Durbin, Matthew Hurles
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Congenica Ltd
- Date of Incorporation 30 Oct, 2012
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
$6.06 M (USD)15as on Dec 31, 2023
-
Net Profit
-$13.94 M (USD)17as on Dec 31, 2023
-
EBITDA
-$14.89 M (USD)18as on Dec 31, 2023
-
Total Equity Funding
$81.91 M (USD)
in 11 rounds
-
Latest Funding Round
$2.81 M (USD), Grant
Jun 17, 2021
-
Investors
Tencent
& 18 more
-
Employee Count
79
as on Dec 31, 2020
-
Acquired by
SeqOne
(Sep 02, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Congenica
Congenica offers a comprehensive portfolio of products and services, including Congenica Platform and Clinical Interpretation Services.
Software for automated genomic data analysis and interpretation
Services for interpreting genetic data in clinical settings
People of Congenica
Unlock access to complete
Unlock access to complete
Funding Insights of Congenica
Congenica has successfully raised a total of $81.91M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $2.81 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Congenica
Congenica has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Tencent, BGI and Downing.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Locked | Locked | Locked | |
|
Health and technology startups are invested in by Puhua Capital.
|
Locked | Locked | Locked | |
|
Startups are targeted for investments by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for Congenica
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Congenica
Investment portfolio details for Congenica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Congenica
Detailed financials for Congenica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Congenica Comparisons
Peer comparison for Congenica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Congenica
Congenica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for multiple health purposes
|
Detailed competitors of Congenica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Congenica
Complete news archive for Congenica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Congenica
Congenica was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Congenica is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Rob Denison is the current CEO of Congenica.
Congenica is a funded company, having raised a total of $81.91M across 11 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Congenica is 79.
Annual revenue of Congenica is $6.06M as on Dec 31, 2023.
Congenica was founded in 2013 and is based in Cambridge, United Kingdom. The company operates in the genomics and healthcare sector, providing a platform for clinical genome analytics. This platform enables detection of complex mutations, filtering of clinically relevant variants, and deep phenotyping. Client data is organized with a focus on outcomes, stored securely, and integrated through intuitive tools for interrogation and sharing.
Congenica's top competitors include Geneoscopy, Poseida Therapeutics and Denali Therapeutics.
Congenica offers Congenica Platform and Clinical Interpretation Services.
Congenica has 19 investors. Key investors include Tencent, BGI, Downing, SeqOne, and Legal & General.